Who are Kate Therapeutics's investors?

Kate Therapeutics's investors include Westlake Village BioPartners, Osage University Partners, Versant Ventures.

How much funding has Kate Therapeutics raised?

Kate Therapeutics has disclosed $123.8M raised across 4 rounds.

Where is Kate Therapeutics headquartered?

Kate Therapeutics is headquartered in San Diego, US.

Kate Therapeutics

San Diego, US · Founded 2020 · Delaware corporation · 4 known investors

Biotech

Founders & leadership

Kevin Forrest, Ph.D.Executive

Board

Clare Ozawa, Ph.D.Board director

Beth Seidenberg, M.D.Board director

Investors · 4

Westlake Village BioPartnersLos Angeles · $100K – $5M

Osage University Partnersreported · 2 sourcesBala Cynwyd

Versant Venturesreported · 2 sourcesSan Francisco · $250K – $5M

Also in the syndicate · 1

UF Innovate | Ventures

Funding

SEC filings, press & company announcements

$123.8M disclosed across 4 rounds · 2021–2024

$51MSeries AJun 2023 · 3 sources
Versant Ventures (lead), Westlake Village BioPartners (lead), Osage University Partners, UF Innovate | Ventures
Source ↗

▶$16MraisedAug 2024 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Clare Ozawa, Ph.D.Director
Kevin Forrest, Ph.D.Executive Officer, Director
Beth Seidenberg, M.D.Director

Offering amount: $16M
Amount sold: $16M
First sale: Feb 2021
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$21.8MraisedAug 2024 · 8 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Clare Ozawa, Ph.D.Director
Kevin Forrest, Ph.D.Executive Officer, Director
Beth Seidenberg, M.D.Director

Offering amount: $23.4M
Amount sold: $21.8M
First sale: May 2024
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$35MraisedAug 2024 · 5 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Kevin Forrest, Ph.D.Executive Officer, Director
Clare Ozawa, Ph.D.Director
Beth Seidenberg, M.D.Director

Offering amount: $35M
Amount sold: $35M
First sale: Aug 2021
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases - BioSpacebiospace.com · Jun 2023

Kate Therapeutics Grants Astellas Pharma Exclusive License To Manufacture And Commercialize KT430 To Treat X-Linked Myotubular Myopathy | Reutersreuters.com · Jun 2023

Kate Therapeutics Raises $51M in Series A Fundingfinsmes.com · Jun 2023

Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseasesprnewswire.com · Jun 2023

Frequently asked questions

Who are Kate Therapeutics's investors?: Kate Therapeutics's investors include Westlake Village BioPartners, Osage University Partners, Versant Ventures.
How much funding has Kate Therapeutics raised?: Kate Therapeutics has disclosed $123.8M raised across 4 rounds.
Where is Kate Therapeutics headquartered?: Kate Therapeutics is headquartered in San Diego, US.